HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fabrazyme confirmatory results

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Genzyme plans to submit results of the principal confirmatory Phase IV study for its Fabry disease therapy Fabrazyme "for labeling purposes early next year," the firm says Sept. 9. A summary study report will be submitted in September. Fabrazyme (agalsidase beta) received accelerated approval for the orphan disease April 24, 2003. According to a preliminary analysis, of the 82 patients enrolled in the double-blind study, those receiving Fabrazyme were 53% less likely than placebo to experience a precursor disease event (p=0.058). Data will be presented at medical meetings in October, including the American Society of Nephrology. The firm is conducting another Phase IV verification study, due to FDA by April 2006...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002646

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel